PUBLISHER: Grand View Research | PRODUCT CODE: 2040548
PUBLISHER: Grand View Research | PRODUCT CODE: 2040548
The global bioprocess automation market size was estimated at USD 8.6 billion in 2025 and is projected to reach USD 22.2 billion by 2033, growing at a CAGR of 12.8% from 2026 to 2033, driven by increasing demand for biologics, progress in AI and robotics, and the need for regulatory compliance.
Rising Demand for Biologics
The rising demand for biologics is among the most significant drivers of the bioprocess automation industry. Over the past decade, there has been a rapid expansion of monoclonal antibody development and vaccine production, gene therapy development, and all other biologic products because these treatments effectively address complicated medical conditions, which include cancer, autoimmune disorders, and rare genetic diseases. For these biologics to remain effective and to maintain high quality, manufacturing procedures must be extremely controlled, scalable, and precise. There is a significant need for fully automated bioprocess solutions because traditional manual or semi-automated production methods are frequently labor-intensive, prone to mistakes, and inadequate to meet the expanding market demand.
Bioprocess automation is becoming essential as healthcare increasingly relies on biologics. It optimizes workflows, enhances consistency, boosts throughput, and reduces costs, variability, and production time using robotics, AI, and advanced monitoring.
Need for Efficiency & Cost Reduction
The need for cost and efficiency reduction largely drives the market for bioprocess automation. Manufacturing biopharmaceuticals is a complicated and resource-intensive process that frequently requires highly qualified staff, careful observation, and strict protocol adherence. The manual and semi-automated processes, which need extensive human effort, lead to operational errors and result in production problems, including batch failures, product defects, and increased production costs. The implementation of automated systems enables businesses to achieve higher productivity levels while reducing their need for human workers and decreasing operational mistakes, which results in more reliable production outcomes.
Automation increases productivity, drastically reduces operating costs, and improves reliability. Manufacturers can more effectively meet growing market demand thanks to automated bioprocessing systems' ability to run continuously with little downtime, optimize resource usage, and speed up production cycles. In an increasingly cost-sensitive healthcare environment, the ability to produce high-quality biologics at a lower cost also helps businesses stay competitive. As a result, the need for cost-effectiveness and operational efficiency keeps driving global investments in bioprocess automation technologies.
Global Bioprocess Automation Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global bioprocess automation market based on product & service, process stage, end use, and region: